RAYALDEE
Peakcalcifediol
NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jun 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Clinical Trials (5)
Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency
Started Dec 2020
674 enrolled
Vitamin D DeficiencyVitamin D Insufficiency
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
Started Nov 2020
171 enrolled
COVID-19CoronavirusSARS-CoV2 Infection
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
Started May 2020
517 enrolled
SARS-CoV 2COVID19SARS (Severe Acute Respiratory Syndrome)+2 more
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
Started Jul 2018
44 enrolled
Secondary Hyperparathyroidism Due to Renal CausesChronic Kidney DiseasesVitamin D Deficiency+1 more
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
Started Jun 2018
69 enrolled
Secondary Hyperparathyroidism Due to Renal CausesVitamin D InsufficiencyCKD Stage 3+1 more
Loss of Exclusivity
LOE Date
Mar 14, 2034
97 months away
Patent Expiry
Mar 14, 2034